EQS News: Mainz Biomed announces Petra Smeltzer Starke as brand ambassador at the company | 18.09.24

Mainz Biomed announces Petra Smeltzer Starke as brand ambassador at the company

Strategic alliance with former White House senior advisor to focus on raising awareness of Mainz Biomed’s products and the importance of early detection

BERKELEY, USA and MAINZ, Germany – September 18, 2024 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetic diagnostics company specializing in the early detection of cancer, today announced the addition of Petra Smeltzer Starke as a brand ambassador for the Company. As a brand ambassador, she will assist the Company in developing and disseminating messages focused on the importance of early detection of colorectal cancer.

“We are excited to have Petra join our team as Brand Ambassador. Her broad and deep experience will be invaluable as we bring our next generation colorectal cancer screening product to market, with the intention to initiate a pivotal PMA study in late 2025,” said Guido Baechler, Chief Executive Officer of Mainz Biomed.

Petra Smeltzer Starke commented: “I am proud and excited to collaborate with Mainz Biomed as they push the boundaries in the early detection of colorectal cancer and, more importantly, the detection of precancerous polyps.”

For more information, please visit Mainz Biomed’s official investor website at mainzbiomed.com/investors/

Follow us to stay informed:
LinkedIn
X (formerly Twitter)
Facebook

About Petra Smeltzer Starke

Petra Smeltzer Starke’s phenomenal career began with studying international business, trade and diplomacy at the Prague School of Economics, while supporting herself as a model. Petra’s passion for fashion translates into her modeling successes, despite Starke graduating top of her class in both her bachelor’s and master’s degrees and moving to the United States to study law at Georgetown University.

Starke was at the top of her class in law school and practiced law at the international law firm O’Melveny & Myers, LLP, where she represented many political nominees and appointees during the Bush administration. Starke was then recruited to the Obama presidential transition and later to the Obama White House, where she served as general counsel to the White House Council of Economic Advisers and as a senior advisor to the president. Starke has advised U.S. presidents and global diplomatic leaders around the world and has built a phenomenal international network. Starke’s expertise helped the Biden-Harris Transition Team – ethics and avoiding conflicts of interest.

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening diseases. The company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert® is marketed in Europe and the United Arab Emirates. The company is currently conducting a pivotal FDA clinical trial for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction (PCR)-based multiplex detection of molecular genetic biomarkers in stool samples. For more information, visit mainzbiomed.com or follow us on LinkedIn, Twitter And Facebook.

For media inquiries

MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
[email protected]

For investor inquiries, please contact: [email protected]

Forward-looking statements

Certain statements in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution should be exercised when relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) failure to achieve expected development and related objectives; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information about these and other factors that could affect the Company’s expectations and projections can be found in its initial filings with the SEC, including its Annual Report on Form 20-F filed on April 9, 2024. The Company’s SEC filings are publicly available on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, which may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.